Latest pharmaceutical Stories

PARSIPPANY, N.J., May 24, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference on Thursday, May 30, 2013 at 4:00 PM Eastern Time at the Waldorf Astoria Hotel in New York, New York. The presentation will be webcast live and can...

- Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p

New Focus of Upsher-Smith.com Captures and Celebrates Life Moments MAPLE GROVE, Minn., May 20, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., a specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, today announced the launch of its newly designed website, upsher-smith.com. The new site celebrates life's moments through images and narratives. As part of the company's mission statement - Advancing...

ATLANTA, May 20, 2013 /PRNewswire/ -- Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company that has developed and is commercializing a unique technology to deter prescription drug abuse today announced that its founder and President, Anthony Soscia, has been chosen as a finalist for the Atlanta Business Chronicle's Health-Care Heroes Awards. The awards are presented annually by the Atlanta Business Chronicle to honor individuals and organizations demonstrating excellence...

Data Evaluating WF10's Therapeutic Impact on Signs and Symptoms of Experimentally Induced Rheumatoid Arthritis in Mice MISSISSAUGA, ON, May 16, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI and Nuvo...

MISSISSAUGA, ON, May 14, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that the United States Patent Office has granted U.S. Patent # 8,435,568, relating to compositions and methods of using WF10 and new derivative formulations for the treatment of allergic asthma, allergic rhinitis...

In the news release, "WuXi PharmaTech Announces First-Quarter 2013 Results," issued earlier today by WuXi PharmaTech (Cayman) Inc. over PR Newswire, we are advised by the company that in the section titled "First-Quarter 2013 Non-GAAP Results," the first sentence of the second, third, fourth and fifth paragraphs, "First-quarter 2012" should read "First-quarter 2013"; also, in the second table of the announcement, "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME," "Other...

SHANGHAI, May 13, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the first quarter of 2013. Highlights Net Revenues Increased 11.7% Year Over Year to $131.9 Million Laboratory Services Net Revenues Grew 12.5% Year Over Year to $97.5 Million...

- Cempra to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, May 13, 2013 - CHAPEL HILL, N.C., May 13, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical needs in the treatment of bacterial infections, today announced the signing of an exclusive license and development agreement for solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings...

RnR Market Research adds new market research report "PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry" to its store. DALLAS, May 10, 2013 /PRNewswire-iReach/ -- A new market research report on early-stage technology transfer collaborations & deals between academia and the pharmaceutical industry says a growing emphasis on academic and non-profit organization partnerships...